Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilonacept in Autoimmune Neurosensory Hearing Loss
NCT02828033Phase 1Unknown
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilonacept in autoimmune sensorineural hearing loss. Primary endpoint: Improvement in hearing in comparison to baseline values at 24 weeks. Status: unknown.
02
Drugs
rilonacept
03
Conditions
autoimmune sensorineural hearing loss
Beyond the preview
Go deeper on NCT02828033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828033.